The disposable kit notifies medical teams of any performance changes during operation and treatment. Credit: Cast Of Thousands/Shutterstock.

Inspira Technologies has announced the development of a new disposable kit featuring a built-in performance monitoring mechanism, designed for the perfusion market.

This product aligns with the company’s strategy to generate recurring revenue and is expected to be compatible with various life-support machines, potentially addressing the $1bn perfusion systems market.

The disposable kit is a single-use product that alerts medical teams to any changes in performance during operation and treatment.

Its unique design is intended to offer a smart, adaptable experience for users.

Inspira Technologies co-founder and CEO Dagi Ben-Noon said: “This new innovation and capability, being integrated into our disposable kit, is expected to be an additional step by Inspira to provide new technologies and user experiences for the purpose of supporting improved safety and patient care.”

See Also:

Inspira is preparing to submit an application for US FDA clearance to market the disposable kit.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Upon approval, the kit will be available for hospitals using the INSPIRA ART100 system.

The ART100 system received FDA 510(k) clearance for cardiopulmonary bypass procedures in May this year.

The company expects the first devices to be deployed in the US by the end of 2024.

Inspira received approval from the Israeli Ministry of Health for its INSPIRA ART100 system in July this year.

The company has developed INSPIRA ART with the aim of transforming the $19bn mechanical ventilation market.

INSPIRA ART features the clip-on HYLA blood sensor, a real-time continuous monitoring technology that alerts physicians to patient condition changes without needing blood samples, helping them make informed decisions.